Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10072-023-07030-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.
J Prev Alzheimers Dis
January 2025
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address:
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).
Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.
Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.
The Symptom Structure and Causal Relationships of Comorbid Anxiety and Depression Among Chinese Primary and Middle School Teachers: A Network Analysis.
Psychol Res Behav Manag
October 2024
College of Education, Hebei Normal University, Shijiazhuang, People's Republic of China.
Background: In China, as educational reforms progress, the characteristics of teachers' work have undergone significant changes, resulting in extremely high levels of stress that can trigger anxiety and depression. Anxiety and depression often co-occur, with two mainstream theories explaining this co-existence: the tripartite model and the diathesis-stress model. However, systematic research focusing on this population is relatively scarce, and the applicability of these models has not been thoroughly tested.
View Article and Find Full Text PDFReal-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.
Lung Cancer (Auckl)
October 2024
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Purpose: Small-cell lung cancer (SCLC) accounts for approximately 10-15% of all lung cancers and is characterized by a high recurrence rate, early metastasis, and poor prognosis. Before the FDA approved lurbinectedin for SCLC that progressed on or after platinum-based chemotherapy in 2020, topotecan was the sole second-line option associated with hematological toxicities and modest efficacy. Lurbinectedin received conditional approval in Korea in September 2022 for metastatic SCLC progression, with the same indications.
View Article and Find Full Text PDFShort-term effects of lifestyle modification on vestibular migraine.
Int J Audiol
October 2024
Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.
Article Synopsis
- The study aimed to evaluate the early effects of lifestyle changes on vestibular migraine symptoms and assess the relationship between a patient's coping ability and the outcomes of these changes.
- In a cohort of 38 patients, significant improvements in dizziness and headache symptoms were observed within the first two weeks of lifestyle modifications, with symptoms stabilizing afterward.
- While better coping skills were associated with lower dizziness and headache levels, they did not predict the extent of symptom improvement; lifestyle changes could serve as a standalone treatment or complement medication.
COVID-19 and Intractable Hiccups: An Apparently Harmless Yet Misleading Manifestation.
Cureus
August 2024
Internal Medicine, University of Maryland Midtown Campus, Baltimore, USA.
Article Synopsis
- - COVID-19 usually shows symptoms like fever, cough, and shortness of breath, but can sometimes present with unusual signs like persistent hiccups and dizziness.
- - The case presented involves a patient whose only symptom was severe hiccups, which led to misdiagnosis and eventually septic shock and death.
- - This situation highlights the importance of recognizing rare COVID-19 symptoms, as they can have serious implications for patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!